

## 5th International Immunonutrition Workshop

# Fatty acids Long-chain fatty acids and inflammation

Philip C. Calder

*Institute of Human Nutrition and Human Development and Health Academic Unit, Faculty of Medicine,  
University of Southampton, Tremona Road, Southampton SO16 6YD, UK*

Inflammation plays a key role in many common conditions and diseases. Fatty acids can influence inflammation through a variety of mechanisms acting from the membrane to the nucleus. They act through cell surface and intracellular receptors that control inflammatory cell signalling and gene expression patterns. Modifications of inflammatory cell membrane fatty acid composition can modify membrane fluidity, lipid raft formation and cell signalling leading to altered gene expression and can alter the pattern of lipid and peptide mediator production. Cells involved in the inflammatory response usually contain a relatively high proportion of the *n*-6 fatty acid arachidonic acid in their membrane phospholipids. Eicosanoids produced from arachidonic acid have well-recognised roles in inflammation. Oral administration of the marine *n*-3 fatty acids EPA and DHA increases the contents of EPA and DHA in the membranes of cells involved in inflammation. This is accompanied by a decrease in the amount of arachidonic acid present. EPA is a substrate for eicosanoid synthesis and these are often less potent than those produced from arachidonic acid. EPA gives rise to E-series resolvins and DHA gives rise to D-series resolvins and protectins. Resolvins and protectins are anti-inflammatory and inflammation resolving. Thus, the exposure of inflammatory cells to different types of fatty acids can influence their function and so has the potential to modify inflammatory processes.

### **Inflammation: Monocyte: Macrophage: Cytokine: Arachidonic acid**

The aim of this article is to provide an update on some of the mechanisms by which long-chain fatty acids can influence inflammatory processes. Inflammation is a key component of normal host defence, which acts to protect the host from infection and other insults. Inflammation initiates the processes of pathogen killing and tissue repair. The five cardinal signs of inflammation are redness, swelling, heat, pain and loss of function. It involves interactions among many cell types and the production of, and responses to, a number of chemical mediators, including cytokines, chemokines, eicosanoids and reactive oxygen species. Self-regulation of the inflammatory response involves the activation of negative feedback mechanisms such as the secretion of anti-inflammatory cytokines, inhibition of pro-inflammatory signalling cascades, shedding of receptors for inflammatory mediators and activation of regulatory cells. Pathological inflammation involves a loss of these

regulatory processes, and may cause excessive, irreparable damage to host tissues<sup>(1)</sup>. The resulting diseases are characterised by markedly increased concentrations of inflammatory markers and of activated inflammatory cells at the site of tissue damage and in the systemic circulation<sup>(1)</sup>. Examples of such inflammatory diseases include rheumatoid arthritis, inflammatory bowel diseases and asthma.

### **Fatty acid functions of relevance to inflammation**

Fatty acids are naturally occurring constituents of the diet. They have metabolic, structural and functional roles within the body, where they act as important sources of energy, major components of all cell membranes, precursors to signalling molecules and regulators of cellular responses<sup>(2)</sup>. Although all fatty acids can be used as energy sources, different fatty acids have different, often unique, structural


**Abbreviations:** COX, cyclooxygenase; IκB, inhibitory subunit of NF-κB; LPS, lipopolysaccharide; TLR, Toll-like receptor.  
**Corresponding author:** Professor Philip C. Calder, fax +44 2380 795255, email pcc@soton.ac.uk

and functional roles and biological activities. Indeed, several fatty acids have roles and activities that oppose one another, indicating that the overall biological outcome will be the result of interactions among several fatty acids. With regard to inflammation it is often considered that it is the PUFA of the *n*-6 and *n*-3 families that are most important, these often acting to oppose one another's actions<sup>(3)</sup>. However, it is now recognised that other fatty acids and fatty acid families are likely also involved in inflammation, with fairly recent work focusing on SFA<sup>(4-6)</sup>. There are a number of general mechanisms by which fatty acid exposures could affect inflammatory cell function, and so inflammatory processes. This article will deal with three of these mechanisms:

- (i) Action directly via surface or intracellular 'fatty acid receptors'.
- (ii) Incorporation into the phospholipids of inflammatory cell membranes, where the fatty acids play important roles assuring the correct environment for membrane protein function, maintaining membrane order ('fluidity'), influencing lipid raft formation and modifying membrane-generated intracellular signalling cascades.
- (iii) Acting as precursors of extracellular signalling molecules such as PG.

### Fatty acids and NF- $\kappa$ B-induced inflammatory gene expression

NF- $\kappa$ B is a key transcription factor involved in up-regulation of inflammatory cytokine, adhesion molecule and cyclooxygenase (COX)-2 genes<sup>(7,8)</sup>. Inactive NF- $\kappa$ B is a trimer localised within the cytosol; it is activated via a signalling cascade triggered by extracellular inflammatory stimuli, and which involves phosphorylation of an inhibitory subunit (inhibitory subunit of NF- $\kappa$ B (I $\kappa$ B)), which then dissociates allowing translocation of the remaining NF- $\kappa$ B dimer to the nucleus<sup>(9)</sup>. Bacterial lipopolysaccharide (LPS), which is also known as endotoxin, induces inflammation by activating NF- $\kappa$ B, as do some inflammatory cytokines and UV irradiation. Cell culture studies with the *n*-3 PUFA EPA and DHA show inhibition of LPS-induced production of COX-2, inducible NO synthase, TNF $\alpha$ , IL-1, IL-6, IL-8 and IL-12 in endothelial cells<sup>(10,11)</sup>, monocytes<sup>(12,13)</sup>, macrophages<sup>(4)</sup> and dendritic cells<sup>(5,14)</sup>. Animal feeding studies with fish oil, a source of EPA and DHA, support the observations made *in vitro* with respect to the effects of *n*-3 PUFA on inflammatory cytokine production. For example, dietary fish oil decreased the production of TNF $\alpha$ , IL-1 $\beta$  and IL-6 by LPS-stimulated macrophages<sup>(15-17)</sup>. Some studies in healthy human subjects have demonstrated that oral fish oil supplements can decrease production of TNF $\alpha$ , IL-1 $\beta$ , IL-6 and various growth factors by LPS-stimulated monocytes or mononuclear cells<sup>(18-23)</sup>, although not all studies confirm this effect. The effects of *n*-3 PUFA have been shown to involve inhibition of LPS-induced activation of NF- $\kappa$ B associated with decreased I $\kappa$ B phosphorylation<sup>(4,24)</sup>. In contrast, SFA, especially lauric acid, enhanced NF- $\kappa$ B



**Fig. 1.** Interaction between pro-inflammatory stimuli and DHA in regulating signalling to NF- $\kappa$ B. Lipopolysaccharide (LPS) and lauric acid both initiate NF- $\kappa$ B signalling through Toll-like receptor (TLR)-4. DHA inhibits responsiveness to both LPS and lauric acid acting to reduce activation of NF- $\kappa$ B. GPR120 is a cell membrane receptor that is linked to inhibition of NF- $\kappa$ B activation. GPR120 mediates some of the anti-inflammatory actions of DHA. A link between GPR120 and TLR-4 is not yet clear.

activation in macrophages<sup>(4)</sup> and dendritic cells<sup>(5)</sup> and so promoted inflammatory gene expression. Lee *et al.*<sup>(4)</sup> found that EPA and DHA, as well as other unsaturated fatty acids (arachidonic, linoleic and oleic acids), were able to prevent the pro-inflammatory effect of lauric acid in macrophages.

It has not been clear how fatty acids can influence activation of NF- $\kappa$ B although their effects might be as far upstream as the plasma membrane. Consistent with this, Lee *et al.*<sup>(4)</sup> showed that the activation of NF- $\kappa$ B and induction of COX-2 expression by lauric acid did not occur in macrophages expressing a dominant-negative mutant of the cell surface LPS receptor, Toll-like receptor (TLR)-4, suggesting that lauric acid somehow interacts with TLR-4 (Fig. 1). Myeloid differentiation primary response gene 88 is a cell membrane-associated adapter protein used by TLR-4 to activate NF- $\kappa$ B. DHA inhibited COX-2 expression in macrophages bearing constitutively active TLR-4 but not in those bearing constitutively active myeloid differentiation primary response gene 88 suggesting that the effects of DHA are at the level of TLR-4<sup>(4)</sup>. More recently, Wong *et al.*<sup>(6)</sup> demonstrated that exposure of macrophages to lauric acid induced association of TLR-4, myeloid differentiation primary response gene 88 and other signalling proteins into organised signalling platforms within the plasma membrane termed membrane rafts in much the same way as LPS acts. Furthermore they showed that DHA inhibited the ability of both LPS and lauric acid to promote recruitment of these signalling proteins into rafts. Thus, the differential effects of fatty acids on inflammatory signalling initiated through TLR-4 and impacting on NF- $\kappa$ B appear to relate to their ability to promote or disrupt membrane raft formation.

### Actions of fatty acids on inflammation via fatty acid receptors

#### Fatty acids, PPAR $\gamma$ and inflammation

PPAR $\gamma$  is a transcription factor that acts in an anti-inflammatory manner<sup>(25)</sup>. It is able to directly regulate

inflammatory gene expression, but it also interferes with the activation of the prototypical pro-inflammatory transcription NF- $\kappa$ B<sup>(26)</sup>. PUFA and their derivatives are endogenous ligands for PPAR $\gamma$ . The *n*-3 PUFA DHA induced PPAR $\gamma$  in dendritic cells and this was associated with reduced production of the pro-inflammatory cytokines TNF $\alpha$  and IL-6 following endotoxin stimulation<sup>(14)</sup>. In addition, DHA induced a number of known PPAR $\gamma$  target genes in dendritic cells, suggesting this as an important anti-inflammatory mechanism of action<sup>(27)</sup>.

#### *Fatty acids, GPR120 and inflammation*

The cell surface G-protein coupled receptor termed GPR120 is highly expressed on inflammatory macrophages, and a GPR120 agonist GW9508 inhibited responsiveness of macrophages to LPS<sup>(28)</sup>. This involved reduced phosphorylation of the I $\kappa$ B and its maintenance in the cytosol (phosphorylated I $\kappa$ B is degraded) and reduced TNF $\alpha$  and IL-6 production. These observations suggest that GPR120 is anti-inflammatory. DHA and another *n*-3 PUFA, EPA, but not arachidonic, palmitic or myristic acids, promoted GPR120-mediated gene activation, although they were much less potent than GW9508. The effects of DHA were further explored<sup>(28)</sup>. Its inhibitory effects on LPS-induced I $\kappa$ B phosphorylation, I $\kappa$ B degradation and TNF $\alpha$ , IL-6 and also on monocyte chemotactic protein-1 production did not occur in GPR120 knockdown cells. These observations suggest that the inhibitory effect of DHA (and probably also those of EPA) on responsiveness to LPS occur via GPR120 (Fig. 1).


#### **Modification of inflammatory cell membrane fatty acid composition and consequent alteration of lipid mediator profiles**

##### *Modification of inflammatory cell membrane fatty acid composition*

PUFA are important constituents of the phospholipids of the membranes of inflammatory cells. Typically these contain a relatively high proportion of the *n*-6 PUFA, arachidonic acid; this is seen in both laboratory animals<sup>(29–38)</sup> and human subjects<sup>(18,21,39–48)</sup>. Increased oral supply of the *n*-3 PUFA EPA and DHA results in an increase in the amount of those fatty acids in inflammatory cells, seen in both laboratory animals<sup>(29,30,32–38)</sup> and human subjects<sup>(18,21,39–44,46–48)</sup>. The increase in content of EPA and DHA happens over the course of days<sup>(49)</sup> to weeks<sup>(42)</sup>, occurs in a dose–response manner<sup>(48)</sup> and is accompanied by a decrease in content of arachidonic acid.

##### *Fatty acid modification of eicosanoid profiles*

Eicosanoids, which include PG, thromboxanes and leukotrienes, are long-recognised mediators and regulators of inflammation. They are formed from C<sub>20</sub> PUFA, typically arachidonic acid, by the COX and lipoxygenase enzymes. In general, arachidonic acid-derived eicosanoids act in a pro-inflammatory way, although this is an oversimplification since it is now recognised that PGE<sub>2</sub>, for



**Fig. 2.** Overview of the mechanisms by which fatty acids can influence inflammatory cell function. Modified from Calder<sup>(64)</sup> with permission from Elsevier.

example, has both pro- and anti-inflammatory effects<sup>(3)</sup>, and that another eicosanoid derived from arachidonic acid, lipoxin A<sub>4</sub>, is anti-inflammatory<sup>(50–53)</sup>.

The decrease in arachidonic acid content of inflammatory cell membranes that occurs with incorporation of the *n*-3 PUFA reduces the availability of the usual eicosanoid substrate and so the production of the major 2-series PG and 4-series leukotrienes is decreased<sup>(17–19,21,39,40,54–56)</sup>. EPA is also a substrate for the COX and lipoxygenase, but the mediators produced have a different structure from the arachidonic acid-derived mediators, and this often influences their potency<sup>(57)</sup>. For example EPA-derived leukotriene B<sub>5</sub> is ten- to 100-fold less potent as a neutrophil chemoattractant compared with leukotriene B<sub>4</sub><sup>(58,59)</sup>. Furthermore, EPA-derived eicosanoids may antagonise the action of those produced from arachidonic acid, as was recently demonstrated for PGD<sub>3</sub> v. PGD<sub>2</sub><sup>(60)</sup>.

#### *Novel anti-inflammatory and inflammation resolving mediators produced from EPA and DHA: resolvins and protectins*

EPA and DHA are substrates for synthesis of fairly recently discovered lipid mediators that are potent anti-inflammatory and inflammation resolving agents. These include resolvins and protectins, which are produced through pathways involving COX and lipoxygenase enzymes<sup>(61–63)</sup>. Examples of the activities are these compounds include the inhibition of transendothelial migration of neutrophils by resolvin E1, resolvin D1 and protectin D1, and inhibition of TNF $\alpha$  and IL-1 $\beta$  production by protectin D1<sup>(63)</sup>.

#### **Therapeutic benefits of the anti-inflammatory actions of *n*-3 fatty acids**

A number of human conditions and diseases have an inflammatory component, and it seems that, irrespective of the body compartment(s) involved, these conditions and

diseases all involve excessive or inappropriate production of inflammatory mediators including eicosanoids and cytokines<sup>(1)</sup>. It is evident that the *n*-3 PUFA EPA and DHA act through multiple interconnected mechanisms (Fig. 2)<sup>(64)</sup> to reduce production of inflammatory eicosanoids and cytokines and to enhance production of anti-inflammatory and inflammation resolving resolvins and protectins. In these ways, *n*-3 PUFA act to oppose the pro-inflammatory actions of SFA and of *n*-6 PUFA. The roles of *n*-3 PUFA in shaping and regulating inflammatory processes and responses suggest that the level of exposure to these fatty acids might be important in determining the development and severity of inflammatory diseases. The recognition that *n*-3 PUFA have anti-inflammatory actions has led to numerous studies supplementing the diet of patients with inflammatory diseases to evaluate clinical benefit. Studies in patients with rheumatoid arthritis have been the most successful among those in patients with an overt inflammatory disease, with a number of trials reporting clinical benefits<sup>(65)</sup>, these benefits being supported by meta-analyses<sup>(66,67)</sup>. Studies in patients with inflammatory bowel diseases (Crohn's disease and ulcerative colitis) provide equivocal findings with some showing some benefits and others not<sup>(68)</sup>. Similarly studies conducted in patients with asthma do not provide a clear picture with most studies conducted in adults not showing a clinical benefit, although there are indications of benefits of *n*-3 PUFA in children and adolescents<sup>(69)</sup>. In most other inflammatory diseases and conditions there are too few studies to draw a clear conclusion of the possible efficacy of *n*-3 PUFA. One reason for these discrepancies may be that the dose of *n*-3 PUFA required to treat different inflammatory conditions is not known, although it is evident that the anti-inflammatory effects of these fatty acids are dose-dependent<sup>(48)</sup>.

### Summary and conclusions

Fatty acids can influence inflammation through a variety of mechanisms, including acting via cell surface and intracellular receptors/sensors that control inflammatory cell signalling and gene expression patterns. Some effects of fatty acids on inflammatory processes involve lipid mediators generated from the fatty acids themselves. Often these fatty acids will be released from cell membrane phospholipids prior to their conversion to the bioactive mediators. Cells involved in the inflammatory response are typically rich in the *n*-6 fatty acid arachidonic acid which is a precursor to inflammatory eicosanoids. The membrane contents of arachidonic acid and of the *n*-3 fatty acids EPA and DHA can be altered through oral administration of EPA and DHA. EPA also gives rise to eicosanoids and these often have differing properties from those of the arachidonic acid-derived analogues, typically being less potent. EPA and DHA give rise to resolvins, and DHA to protectins which are anti-inflammatory and inflammation resolving. These relatively recently discovered mediators provide a novel mechanism by which *n*-3 PUFA can influence inflammatory processes. As a result of their anti-inflammatory actions *n*-3 PUFA may have therapeutic

efficacy in inflammatory diseases. This is well described in rheumatoid arthritis, but less so in other inflammatory conditions. Currently the multiple mechanisms of action of fatty acids on inflammation are not fully integrated, but it seems likely that alterations in membrane composition are a key event since such alterations can influence lipid mediator profiles, membrane receptor function and cell signalling processes. Future work will focus on defining the membrane structure–function interaction that is associated with different fatty acid compositions and on describing the biosynthesis and actions of novel lipid mediators like resolvins and protectins and mechanisms that underlie their effects.

### Acknowledgements

The author serves the Danone Scientific Advisory Board on Immune Function and on the Scientific Advisory Board of Aker Biomarine. He acts as a consultant to the Danone Research Centre for Specialised Nutrition, and in the past 5 years he has acted as a consultant to Mead Johnson Nutritionals, Vifor Pharma, Equazen and Amarin Corporation. He has received speaking honoraria from Solvay Healthcare, Solvay Pharmaceuticals, Pronova Biocare, Fresenius Kabi, B. Braun, Abbott Nutrition, Baxter Healthcare, Nestle and Unilever. He currently receives research funding from the Vifor Pharma and Abbott Nutrition. He is elected President of the International Society for the Study of Fatty Acids and Lipids, an organisation that is partly supported by corporate membership fees, mainly the food and supplements industries. He is on the Boards of Directors of ILSI Europe and the European Nutraceuticals Association, organisations that are partly supported by funds from the food and supplements industries.

### References

1. Calder PC, Albers R, Antoine JM *et al.* (2009) Inflammatory disease processes and interactions with nutrition. *Br J Nutr* **101**, S1–S45.
2. Calder PC & Burdge GC (2004) Fatty acids. In: *Bioactive Lipids*, pp. 1–36 [Nicolaou A and Kafatos G, editors], Bridgewater: The Oily Press.
3. Calder PC (2009) Polyunsaturated fatty acids and inflammatory processes: new twists in an old tale. *Biochimie* **91**, 791–795.
4. Lee JY, Sohn KH, Rhee SH *et al.* (2001) Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. *J Biol Chem* **276**, 16683–16689.
5. Weatherill AR, Lee JY, Zhao L *et al.* (2005) Saturated and polyunsaturated fatty acids reciprocally modulate dendritic cell functions mediated through TLR4. *J Immunol* **174**, 5390–5397.
6. Wong SW, Kwon MJ, Choi AM *et al.* (2009) Fatty acids modulate Toll-like receptor 4 activation through regulation of receptor dimerization and recruitment into lipid rafts in a reactive oxygen species-dependent manner. *J Biol Chem* **284**, 27384–27392.

7. Kumar A, Takada Y, Boriek AM *et al.* (2004) Nuclear factor- $\kappa$ B: its role in health and disease. *J Mol Med* **82**, 434–448.
8. Sigal LH (2006) Basic science for the clinician 39: NF- $\kappa$ B-function, activation, control, and consequences. *J Clin Rheumatol* **12**, 207–211.
9. Perkins ND (2007) Integrating cell-signalling pathways with NF- $\kappa$ B and I $\kappa$ K function. *Nat Rev Mol Cell Biol* **8**, 49–62.
10. De Caterina R & Libby P (1996) Control of endothelial leukocyte adhesion molecules by fatty acids. *Lipids* **31**, S57–S63.
11. Khalfoun B, Thibault F, Watier H *et al.* (1997) Docosahexaenoic and eicosapentaenoic acids inhibit *in vitro* human endothelial cell production of interleukin-6. *Adv Exp Biol Med* **400**, 589–597.
12. Lo CJ, Chiu KC, Fu M *et al.* (1999) Fish oil decreases macrophage tumor necrosis factor gene transcription by altering the NF- $\kappa$ B activity. *J Surg Res* **82**, 216–221.
13. Babcock TA, Novak T, Ong E *et al.* (2002) Modulation of lipopolysaccharide-stimulated macrophage tumor necrosis factor- $\alpha$  production by  $\omega$ -3 fatty acid is associated with differential cyclooxygenase-2 protein expression and is independent of interleukin-10. *J Surg Res* **107**, 135–139.
14. Kong W, Yen JH, Vassiliou E *et al.* (2010) Docosahexaenoic acid prevents dendritic cell maturation and *in vitro* and *in vivo* expression of the IL-12 cytokine family. *Lipids Health Dis* **9**, 12.
15. Billiar T, Bankey P, Svingen B *et al.* (1988) Fatty acid uptake and Kupffer cell function: fish oil alters eicosanoid and monokine production to endotoxin stimulation. *Surgery* **104**, 343–349.
16. Renier G, Skamene E, de Sanctis J *et al.* (1993) Dietary *n*-3 polyunsaturated fatty acids prevent the development of atherosclerotic lesions in mice: modulation of macrophage secretory activities. *Arterioscler Thomb* **13**, 1515–1524.
17. Yaqoob P & Calder PC (1995) Effects of dietary lipid manipulation upon inflammatory mediator production by murine macrophages. *Cell Immunol* **163**, 120–128.
18. Endres S, Ghorbani R, Kelley VE *et al.* (1989) The effect of dietary supplementation with *n*-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. *N Engl J Med* **320**, 265–271.
19. Meydani SN, Endres S, Woods MM *et al.* (1991) Oral (*n*-3) fatty acid supplementation suppresses cytokine production and lymphocyte proliferation: comparison between young and older women. *J Nutr* **121**, 547–555.
20. Abbate R, Gori AM, Martini F *et al.* (1996) N-3 PUFA supplementation, monocyte PCA expression and interleukin-6 production. *Prostaglandin Leukotr Essent Fatty Acids* **54**, 439–444.
21. Caughey GE, Mantzioris E, Gibson RA *et al.* (1996) The effect on human tumor necrosis factor  $\alpha$  and interleukin 1 $\beta$  production of diets enriched in *n*-3 fatty acids from vegetable oil or fish oil. *Am J Clin Nutr* **63**, 116–122.
22. Baumann KH, Hessel F, Larass I *et al.* (1999) Dietary  $\omega$ -3,  $\omega$ -6, and  $\omega$ -9 unsaturated fatty acids and growth factor and cytokine gene expression in unstimulated and stimulated monocytes. *Arterioscler Thromb Vasc Biol* **19**, 59–66.
23. Trebble T, Arden NK, Stroud MA *et al.* (2003) Inhibition of tumour necrosis factor- $\alpha$  and interleukin-6 production by mononuclear cells following dietary fish-oil supplementation in healthy men and response to antioxidant co-supplementation. *Br J Nutr* **90**, 405–412.
24. Novak TE, Babcock TA, Jho DH *et al.* (2003) NF-kappa B inhibition by omega -3 fatty acids modulates LPS-stimulated macrophage TNF- $\alpha$  transcription. *Am J Physiol* **284**, L84–L89.
25. Szanto A & Nagy L (2008) The many faces of PPAR $\gamma$ : anti-inflammatory by any means? *Immunobiol* **213**, 789–803.
26. Van den Berghe W, Vermeulen L, Delerive P *et al.* (2003) A paradigm for gene regulation: inflammation, NF- $\kappa$ B and PPAR. *Adv Exp Med Biol* **544**, 181–196.
27. Zapata-Gonzalez F, Rueda F, Petriz J *et al.* (2008) Human dendritic cell activities are modulated by the omega-3 fatty acid, docosahexaenoic acid, mainly through PPAR (gamma):RXR heterodimers: comparison with other polyunsaturated fatty acids. *J Leukoc Biol* **84**, 1172–1182.
28. Oh DY, Talukdar S, Bae EJ *et al.* (2010) GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. *Cell* **142**, 687–698.
29. Lokesh BR, Hsieh HL & Kinsella JE (1986) Peritoneal macrophages from mice fed dietary (*n*-3) polyunsaturated fatty acids secrete low levels of prostaglandins. *J Nutr* **116**, 2547–2552.
30. Brouard C & Pascaud M (1990) Effects of moderate dietary supplementations with *n*-3 fatty acids on macrophage and lymphocyte phospholipids and macrophage eicosanoid synthesis in the rat. *Biochim Biophys Acta* **1047**, 19–28.
31. Calder PC, Bond JA, Harvey DJ *et al.* (1990) Uptake and incorporation of saturated and unsaturated fatty acids into macrophage lipids and their effect upon macrophage adhesion and phagocytosis. *Biochem J* **269**, 807–814.
32. Chapkin RS, Akoh CC & Lewis RE (1992) Dietary fish oil modulation of *in vivo* peritoneal macrophage leukotriene production and phagocytosis. *J Nutr Biochem* **3**, 599–604.
33. Surette ME, Whelan J, Lu G *et al.* (1995) Dietary *n*-3 polyunsaturated fatty acids modify Syrian hamster platelet and macrophage phospholipid fatty acyl composition and eicosanoid synthesis: a controlled study. *Biochim Biophys Acta* **1255**, 185–191.
34. Fritsche KL, Alexander DW, Cassity NA *et al.* (1993) Maternally-supplied fish oil alters piglet immune cell fatty acid profile and eicosanoid production. *Lipids* **28**, 677–682.
35. Palombo JD, DeMichele SJ, Lydon E *et al.* (1997) Cyclic vs continuous enteral feeding with omega-3 and gamma-linolenic fatty acids: effects on modulation of phospholipid fatty acids in rat lung and liver immune cells. *J Parent Enter Nutr* **21**, 123–132.
36. Careaga-Houck M & Sprecher H (1989) Effect of a fish oil diet on the composition of rat neutrophil lipids and the molecular species of choline and ethanolamine glycerophospholipids. *J Lipid Res* **30**, 77–87.
37. James MJ, Cleland LG, Gibson RA *et al.* (1991) Interaction between fish and vegetable oils in relation to rat leucocyte leukotriene production. *J Nutr* **121**, 631–637.
38. de La Puerta Vázquez R, Martínez-Domínguez E, Sánchez Perona J *et al.* (2004) Effects of different dietary oils on inflammatory mediator generation and fatty acid composition in rat neutrophils. *Metabolism* **53**, 59–65.
39. Lee TH, Hoover RL, Williams JD *et al.* (1985) Effects of dietary enrichment with eicosapentaenoic acid and docosahexaenoic acid on *in vitro* neutrophil and monocyte leukotriene generation and neutrophil function. *N Engl J Med* **312**, 1217–1224.
40. Sperling RI, Benincaso AI, Knoell CT *et al.* (1993) Dietary  $\omega$ -3 polyunsaturated fatty acids inhibit phosphoinositide formation and chemotaxis in neutrophils. *J Clin Invest* **91**, 651–960.
41. Gibney MJ & Hunter B (1993) The effects of short- and long-term supplementation with fish oil on the incorporation of *n*-3 polyunsaturated fatty acids into cells of the immune system in healthy volunteers. *Eur J Clin Nutr* **47**, 255–259.

42. Yaqoob P, Pala HS, Cortina-Borja M *et al.* (2000) Encapsulated fish oil enriched in  $\alpha$ -tocopherol alters plasma phospholipid and mononuclear cell fatty acid compositions but not mononuclear cell functions. *Eur J Clin Invest* **30**, 260–274.
43. Healy DA, Wallace FA, Miles EA *et al.* (2000) The effect of low to moderate amounts of dietary fish oil on neutrophil lipid composition and function. *Lipids* **35**, 763–768.
44. Thies F, Nebe-von-Caron G, Powell JR *et al.* (2001) Dietary supplementation with  $\omega$ -linolenic acid or fish oil decreases T lymphocyte proliferation in healthy older humans. *J Nutr* **131**, 1918–1927.
45. Kew S, Banerjee T, Minihane AM *et al.* (2003) Relation between the fatty acid composition of peripheral blood mononuclear cells and measures of immune cell function in healthy, free-living subjects aged 25–72 y. *Am J Clin Nutr* **77**, 1278–1286.
46. Kew S, Mesa MD, Tricon S *et al.* (2004) Effects of oils rich in eicosapentaenoic and docosahexaenoic acids on immune cell composition and function in healthy humans. *Am J Clin Nutr* **79**, 674–681.
47. Miles EA, Banerjee T & Calder PC (2004) The influence of different combinations of gamma-linolenic, stearidonic and eicosapentaenoic acids on the fatty acid composition of blood lipids and mononuclear cells in human volunteers. *Prostaglandin Leukotr Essent Fatty Acids* **70**, 529–538.
48. Rees D, Miles EA, Banerjee T *et al.* (2006) Dose-related effects of eicosapentaenoic acid on innate immune function in healthy humans: a comparison of young and older men. *Am J Clin Nutr* **83**, 331–342.
49. Faber J, Berkhout M, Vos AP *et al.* (2011) Supplementation with a fish oil-enriched, high-protein medical food leads to rapid incorporation of EPA into white blood cells and modulates immune responses within one week in healthy men and women. *J Nutr* **141**, 964–970.
50. Levy BD, Clish CB, Schmidt B *et al.* (2001) Lipid mediator class switching during acute inflammation: signals in resolution. *Nat Immunol* **2**, 612–619.
51. Vachier I, Chanez P, Bonnans C *et al.* (2002) Endogenous anti-inflammatory mediators from arachidonate in human neutrophils. *Biochem Biophys Res Commun* **290**, 219–224.
52. Gewirtz AT, Collier-Hyams LS, Young AN *et al.* (2002) Lipoxin A4 analogs attenuate induction of intestinal epithelial proinflammatory gene expression and reduce the severity of dextran sodium sulfate-induced colitis. *J Immunol* **168**, 5260–5267.
53. Serhan CN, Jain A, Marleau S *et al.* (2003) Reduced inflammation and tissue damage in transgenic rabbits overexpressing 15-lipoxygenase and endogenous anti-inflammatory lipid mediators. *J Immunol* **171**, 6856–6865.
54. Chapkin RS, Akoh CC & Miller CC (1991) Influence of dietary n-3 fatty acids on macrophage glycerophospholipid molecular species and peptidoleukotriene synthesis. *J Lipid Res* **32**, 1205–1213.
55. Peterson LD, Jeffery NM, Thies F *et al.* (1998) Eicosapentaenoic and docosahexaenoic acids alter rat spleen leukocyte fatty acid composition and prostaglandin E2 production but have different effects on lymphocyte functions and cell-mediated immunity. *Lipids* **33**, 171–180.
56. Von Schacky C, Kiefl R, Jendraschak E *et al.* (1993) N-3 fatty acids and cysteinyl-leukotriene formation in humans *in vitro*, *ex vivo* and *in vivo*. *J Lab Clin Med* **121**, 302–309.
57. Wada M, DeLong CJ, Hong YH *et al.* (2007) Enzymes and receptors of prostaglandin pathways with arachidonic acid-derived versus eicosapentaenoic acid-derived substrates and products. *J Biol Chem* **282**, 22254–22266.
58. Goldman DW, Pickett WC & Goetzl EJ (1983) Human neutrophil chemotactic and degranulating activities of leukotriene B<sub>5</sub> (LTB<sub>5</sub>) derived from eicosapentaenoic acid. *Biochem Biophys Res Commun* **117**, 282–288.
59. Lee TH, Mencia-Huerta JM, Shih C *et al.* (1984) Characterization and biologic properties of 5,12-dihydroxy derivatives of eicosapentaenoic acid, including leukotriene-B5 and the double lipoxygenase product. *J Biol Chem* **259**, 2383–2389.
60. Tull SP, Yates CM, Maskrey BH *et al.* (2009) Omega-3 Fatty acids and inflammation: novel interactions reveal a new step in neutrophil recruitment. *PLoS Biol* **7**, e1000177.
61. Serhan CN, Clish CB, Brannon J *et al.* (2000) Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. *J Exp Med* **192**, 1197–1204.
62. Serhan CN, Hong S, Gronert K *et al.* (2002) Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter pro-inflammation signals. *J Exp Med* **196**, 1025–1037.
63. Serhan CN, Chiang N & van Dyke TE (2008) Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. *Nat Rev Immunol* **8**, 349–361.
64. Calder PC (2011) Fatty acids and inflammation: the cutting edge between food and pharma. *Eur J Pharmacol* **668**, Suppl. 1, S50–S58.
65. Calder PC (2008) PUFA, inflammatory processes and rheumatoid arthritis. *Proc Nutr Soc* **67**, 409–418.
66. Fortin PR, Lew RA, Liang MH *et al.* (1995) Validation of a meta-analysis: the effects of fish oil in rheumatoid arthritis. *J Clin Epidemiol* **48**, 1379–1390.
67. Goldberg RJ & Katz J (2007) A meta-analysis of the analgesic effects of omega-3 polyunsaturated fatty acid supplementation for inflammatory joint pain. *Pain* **129**, 210–223.
68. Calder PC (2008) Polyunsaturated fatty acids, inflammatory processes and inflammatory bowel diseases. *Mol Nutr Food Res* **52**, 885–897.
69. Calder PC (2006) N-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. *Am J Clin Nutr* **83**, 1505S–1519S.